Effects of Continuous Glucose Monitoring on Impaired Awareness of Hypoglycemia in Older Adults With Type 1 Diabetes: A Post Hoc Analysis of the WISDM Study by Anika Bilal (16701942)

Image 3_VdPAT1 encoding a pantothenate transporter protein is required for fungal growth, mycelial penetration and pathogenicity of Verticillium dahliae.jpeg by Stephen Mwangi Kamau (20576060)

“…In previous study, we identified a pantothenate transporter gene (VdPAT1) in V. dahliae which can be induced by root exudates from a susceptible cotton variety.…”

Table 1_VdPAT1 encoding a pantothenate transporter protein is required for fungal growth, mycelial penetration and pathogenicity of Verticillium dahliae.xlsx by Stephen Mwangi Kamau (20576060)

“…In previous study, we identified a pantothenate transporter gene (VdPAT1) in V. dahliae which can be induced by root exudates from a susceptible cotton variety.…”

Image 1_VdPAT1 encoding a pantothenate transporter protein is required for fungal growth, mycelial penetration and pathogenicity of Verticillium dahliae.jpeg by Stephen Mwangi Kamau (20576060)

“…In previous study, we identified a pantothenate transporter gene (VdPAT1) in V. dahliae which can be induced by root exudates from a susceptible cotton variety.…”

Image 2_VdPAT1 encoding a pantothenate transporter protein is required for fungal growth, mycelial penetration and pathogenicity of Verticillium dahliae.jpeg by Stephen Mwangi Kamau (20576060)

“…In previous study, we identified a pantothenate transporter gene (VdPAT1) in V. dahliae which can be induced by root exudates from a susceptible cotton variety.…”

Table 1_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

“…However, the change in age-standardized rates from 1990 to 2021 declined significantly. The association between the Socio-demographic Index (SDI) and the burden of amputations in 2021 was not linear. …”

Table 4_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

“…However, the change in age-standardized rates from 1990 to 2021 declined significantly. The association between the Socio-demographic Index (SDI) and the burden of amputations in 2021 was not linear. …”

Table 3_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

“…However, the change in age-standardized rates from 1990 to 2021 declined significantly. The association between the Socio-demographic Index (SDI) and the burden of amputations in 2021 was not linear. …”

Table 2_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

“…However, the change in age-standardized rates from 1990 to 2021 declined significantly. The association between the Socio-demographic Index (SDI) and the burden of amputations in 2021 was not linear. …”

Table 5_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

“…However, the change in age-standardized rates from 1990 to 2021 declined significantly. The association between the Socio-demographic Index (SDI) and the burden of amputations in 2021 was not linear. …”

Table 6_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

“…However, the change in age-standardized rates from 1990 to 2021 declined significantly. The association between the Socio-demographic Index (SDI) and the burden of amputations in 2021 was not linear. …”

DataSheet1_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

“…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”

DataSheet2_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

“…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”

DataSheet3_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

“…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”

Table_1_Characterization of the microbial communities and their correlations with volatile flavor compounds and physicochemical factors in Bashang suancai, a traditional Chinese pi... by Yuan Liu (88411)

“…The bacterial community diversity decreased significantly following 7 days of fermentation. …”

Image 1_Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.jpeg by Xin Fei (20466992)

“…The patient was then administered a combination of anlotinib and tislelizumab. After treatment, the patient’s symptoms were controlled, tumor marker levels decreased, and imaging showed significant improvement. …”

Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”